| scholarly article | Q13442814 |
| P2093 | author name string | N. Frenkel | |
| R. R. Spaete | |||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | virus | Q808 |
| molecular cloning | Q408351 | ||
| genetic vector | Q427389 | ||
| vector-borne disease | Q2083837 | ||
| amplicon | Q2844457 | ||
| P304 | page(s) | 295-304 | |
| P577 | publication date | 1982-08-01 | |
| P1433 | published in | Cell | Q655814 |
| P1476 | title | The herpes simplex virus amplicon: A new eucaryotic defective-virus cloning-amplifying vector | |
| P478 | volume | 30 |
| Q36872106 | A 67-base-pair segment from the Ori-S region of herpes simplex virus type 1 encodes origin function |
| Q37396712 | A DNA binding protein specific for an origin of replication of herpes simplex virus type 1. |
| Q35222291 | A brief history of gene therapy |
| Q43244050 | A defective HSV-1 vector expresses Escherichia coli beta-galactosidase in cultured peripheral neurons |
| Q37248409 | A deletion mutant in the human cytomegalovirus gene encoding IE1(491aa) is replication defective due to a failure in autoregulation |
| Q36831621 | A host cell protein binds to a highly conserved sequence element (pac-2) within the cytomegalovirus a sequence. |
| Q35873295 | A hybrid herpesvirus infectious vector based on Epstein-Barr virus and herpes simplex virus type 1 for gene transfer into human cells in vitro and in vivo |
| Q37409686 | A method for identifying the viral genes required for herpesvirus DNA replication |
| Q40547095 | A new method to propagate defective HSV-1 vectors |
| Q36655306 | A novel class of transcripts expressed with late kinetics in the absence of ICP4 spans the junction between the long and short segments of the herpes simplex virus type 1 genome |
| Q36891387 | A putative origin of replication of plasmids derived from Epstein-Barr virus is composed of two cis-acting components |
| Q40412983 | A truncated herpes simplex virus origin binding protein which contains the carboxyl terminal origin binding domain binds to the origin of replication but does not alter its conformation |
| Q40524547 | Advances in cancer gene therapy |
| Q37217245 | Advances in high-capacity extrachromosomal vector technology: episomal maintenance, vector delivery, and transgene expression. |
| Q36256746 | Altering central nervous system physiology with a defective herpes simplex virus vector expressing the glucose transporter gene |
| Q40571051 | Amplicon-based herpes simplex virus vectors. |
| Q40390640 | Amplification of acidic endothelial cell growth factor (ECGF) gene sequences in hamster DDT1-MF2 tumor cells |
| Q40137260 | An HSV-1 amplicon system for prostate-specific expression of ICP4 to complement oncolytic viral replication for in vitro and in vivo treatment of prostate cancer cells |
| Q44858702 | An adenoviral vector expressing the glucose transporter protects cultured striatal neurons from 3-nitropropionic acid |
| Q77106472 | An infectious transfer and expression system for genomic DNA loci in human and mouse cells |
| Q40448525 | Analysis of Ori-S sequence of HSV-1: identification of one functional DNA binding domain. |
| Q36822278 | Analysis of an origin of DNA replication located at the L terminus of the genome of pseudorabies virus |
| Q40140792 | Analysis of gene expression using Simian Virus 40 vectors |
| Q39782364 | Analysis of herpes simplex virus type 1 DNA packaging signal mutations in the context of the viral genome |
| Q40106342 | Analysis of the herpes simplex virus type 1 OriS sequence: mapping of functional domains |
| Q43934769 | Antitumor effects on human melanoma xenografts of an amplicon vector transducing the herpes thymidine kinase gene followed by ganciclovir |
| Q40651385 | Application of an immunoperoxidase monolayer assay for the detection of arboviral antibodies |
| Q50798624 | Assessment of a cellular vaccination approach consisting of crawling dendritic cells (CDCs) transduced with HSV-1-Deltapac vectors. |
| Q36946568 | BK Virus-Plasmid Expression Vector That Persists Episomally in Human Cells and Shuttles into Escherichia coli |
| Q38345181 | Binding of the herpes simplex virus type 1 UL9 gene product to an origin of viral DNA replication |
| Q40065708 | Boundaries and structure of human cytomegalovirus oriLyt, a complex origin for lytic-phase DNA replication |
| Q39874400 | Branched structures in the intracellular DNA of herpes simplex virus type 1. |
| Q45236484 | Cell culture amplification of a defective Marek's disease virus |
| Q36255482 | Cell engineering for muscle gene therapy: Extemporaneous production of retroviral vector packaging macrophages using defective herpes simplex virus type 1 vectors harbouring gag, pol, env genes |
| Q33782614 | Cellular transcription factors enhance herpes simplex virus type 1 oriS-dependent DNA replication. |
| Q39538972 | Characterisation of a human herpesvirus 6 variant A 'amplicon' and replication modulation by U94-Rep 'latency gene'. |
| Q45797434 | Characterization of the TRs/IRS origin of DNA replication of herpes simplex virus Type 1 |
| Q35885882 | Circularization and cleavage of guinea pig cytomegalovirus genomes |
| Q40373850 | Circularization of the herpes simplex virus type 1 genome upon lytic infection |
| Q40138262 | Class I defective herpes simplex virus DNA as a molecular cloning vehicle in eucaryotic cells |
| Q36862725 | Cloning and characterization of oriL2, a large palindromic DNA replication origin of herpes simplex virus type 2. |
| Q29030728 | Cloning human herpes virus 6A genome into bacterial artificial chromosomes and study of DNA replication intermediates |
| Q36888407 | Cloning, sequencing, and functional analysis of oriL, a herpes simplex virus type 1 origin of DNA synthesis |
| Q43583250 | Combination suicide/cytokine gene therapy as adjuvants to a defective herpes simplex virus-based cancer vaccine. |
| Q37193031 | Comparative analysis of human cytomegalovirus a-sequence in multiple clinical isolates by using polymerase chain reaction and restriction fragment length polymorphism assays. |
| Q37784704 | Constitutive and Inducible Innate Responses in Cells Infected by HSV-1-Derived Amplicon Vectors |
| Q36686357 | Construction and properties of a recombinant herpes simplex virus 1 lacking both S-component origins of DNA synthesis |
| Q34464526 | Construction of an excisable bacterial artificial chromosome containing a full-length infectious clone of herpes simplex virus type 1: viruses reconstituted from the clone exhibit wild-type properties in vitro and in vivo |
| Q38804605 | Construction of recombinant pseudorabies viruses by using PRV BACs deficient in IE180 or pac sequences: Application of vBAC90D recombinant virus to production of PRV amplicons. |
| Q34074791 | Current status of viral gene therapy for brain tumours |
| Q34070154 | Cytomegalovirus bacterial artificial chromosomes: a new herpesvirus vector approach |
| Q40065369 | Cytotoxicity of a replication-defective mutant of herpes simplex virus type 1 |
| Q41559090 | DNA labeled during phosphonoacetate inhibition and following its reversal in herpesvirus infected cells |
| Q35564463 | DNA sequence of the region in the genome of herpes simplex virus type 1 containing the genes for DNA polymerase and the major DNA binding protein. |
| Q39879535 | Defective herpes simplex virus type 1 vectors harboring gag, pol, and env genes can be used to rescue defective retrovirus vectors |
| Q40913368 | Defective viral vectors as agents for gene transfer in the nervous system |
| Q35753517 | Development of herpesvirus-based episomally maintained gene delivery vectors |
| Q37949279 | Development of new cell lines for animal cell biotechnology |
| Q40699522 | Development of new expression vector based on Pseudorabies virus amplicons: application to human insulin expression |
| Q45756222 | Direct gene transfer into human epileptogenic hippocampal tissue with an adeno-associated virus vector: implications for a gene therapy approach to epilepsy |
| Q80674687 | Early STAT1 activation after systemic delivery of HSV amplicon vectors suppresses transcription of the vector-encoded transgene |
| Q35750430 | Effect of promoter strength on protein expression and immunogenicity of an HSV-1 amplicon vector encoding HIV-1 Gag. |
| Q45729782 | Effects of gene transfer into cultured CNS neurons with a replication-defective herpes simplex virus type 1 vector |
| Q33845102 | Effects of mutations within the herpes simplex virus type 1 DNA encapsidation signal on packaging efficiency |
| Q40324547 | Efficient site-specific integration of large transgenes by an enhanced herpes simplex virus/adeno-associated virus hybrid amplicon vector |
| Q62971299 | Engineering Herpes Simplex |
| Q91652419 | Enhanced Production of Herpes Simplex Virus 1 Amplicon Vectors by Gene Modification and Optimization of Packaging Cell Growth Medium |
| Q27480392 | Enzymatic characterization of hepatitis C virus NS3/4A complexes expressed in mammalian cells by using the herpes simplex virus amplicon system |
| Q36683468 | Epstein-Barr virus (EBV) recombinants: use of positive selection markers to rescue mutants in EBV-negative B-lymphoma cells |
| Q39881506 | Equimolar generation of the four possible arrangements of adjacent L components in herpes simplex virus type 1 replicative intermediates. |
| Q45764657 | Expression of L1 in primary astrocytes via a defective herpes simplex virus vector promotes neurite outgrowth and neural cell migration |
| Q39873071 | Expression of an equine herpesvirus 1 ICP22/ICP27 hybrid protein encoded by defective interfering particles associated with persistent infection. |
| Q34363528 | Expression of human immunodeficiency virus type 1 gp120 from herpes simplex virus type 1-derived amplicons results in potent, specific, and durable cellular and humoral immune responses |
| Q38307531 | Expression of the varicella-zoster virus origin-binding protein and analysis of its site-specific DNA-binding properties. |
| Q40811145 | Expression of vhs and VP16 during HSV-1 helper virus-free amplicon packaging enhances titers |
| Q31920166 | Flow cytometric assessment of transduction efficiency and cytotoxicity of herpes simplex virus type 1-based amplicon vectors |
| Q40494835 | Fragments from both termini of the herpes simplex virus type 1 genome contain signals required for the encapsidation of viral DNA |
| Q36867220 | Functional domains within the a sequence involved in the cleavage-packaging of herpes simplex virus DNA. |
| Q40606308 | Functional expression of ATM gene carried by HSV amplicon vector in vitro and in vivo |
| Q33781982 | Functional identification and analysis of cis-acting sequences which mediate genome cleavage and packaging in human herpesvirus 6 |
| Q36781706 | Functional mapping and DNA sequence of an equine herpesvirus 1 origin of replication. |
| Q33210210 | Gene expression profiles associated with survival of individual rat dentate cells after endogenous corticosteroid deprivation |
| Q34119491 | Gene therapy for Parkinson's disease: review and update |
| Q37610257 | Gene therapy for malignant brain tumors |
| Q34997896 | Gene therapy for the central nervous system in the lysosomal storage disorders |
| Q33837123 | Gene therapy in the CNS. |
| Q44493199 | Gene transfer and in vivo promoter analysis of the rat progesterone receptor using a herpes simplex virus viral vector |
| Q39581687 | Gene transfer into the nervous system |
| Q44241094 | Gene transfer of NMDAR1 subunit sequences to the rat CNS using herpes simplex virus vectors interfered with habituation. |
| Q39211259 | Generation of high-titer defective HSV-1 vectors |
| Q39989655 | Generation of high-titer defective HSV-1 vectors |
| Q36908014 | Genetic and phenotypic analysis of herpes simplex virus type 1 mutants conditionally resistant to immune cytolysis |
| Q36832257 | Genetic evidence for multiple nuclear functions of the herpes simplex virus ICP8 DNA-binding protein |
| Q44916386 | HSV-1 amplicon vector-mediated expression of ATM cDNA and correction of the ataxia-telangiectasia cellular phenotype |
| Q40746235 | HSV-1 amplicon vectors |
| Q36897379 | HSV-1 amplicon vectors: a promising and versatile tool for gene delivery. |
| Q39974606 | HSV-1 amplicon viral vector-mediated gene transfer to human bone marrow-derived mesenchymal stem cells. |
| Q58995392 | HSV-1 as a Model for Emerging Gene Delivery Vehicles |
| Q36288901 | HSV-1-based amplicon vectors: design and applications |
| Q33995752 | HSV-1-based vectors for gene therapy of neurological diseases and brain tumors: part II. Vector systems and applications |
| Q37528088 | HSV-1-derived amplicon vectors: recent technological improvements and remaining difficulties--a review |
| Q35870965 | Helper virus-free transfer of herpes simplex virus type 1 plasmid vectors into neural cells. |
| Q40604183 | Helper-free HSV-1 amplicons elicit a markedly less robust innate immune response in the CNS. |
| Q39923388 | Herpes Virus Amplicon Vectors |
| Q33846286 | Herpes simplex virus 1 helicase-primase: a complex of three herpes-encoded gene products |
| Q34699896 | Herpes simplex virus DNA packaging sequences adopt novel structures that are specifically recognized by a component of the cleavage and packaging machinery |
| Q33634580 | Herpes simplex virus DNA replication: the UL9 gene encodes an origin-binding protein |
| Q36859541 | Herpes simplex virus amplicon: cleavage of concatemeric DNA is linked to packaging and involves amplification of the terminally reiterated a sequence. |
| Q36918697 | Herpes simplex virus amplicon: effect of size on replication of constructed defective genomes containing eucaryotic DNA sequences |
| Q36792982 | Herpes simplex virus induces the replication of foreign DNA. |
| Q40132227 | Herpes simplex virus infection generates large tandemly reiterated simian virus 40 DNA molecules in a transformed hamster cell line. |
| Q36780584 | Herpes simplex virus type 1 DNA synthesis requires the product of the UL8 gene: isolation and characterization of an ICP6::lacZ insertion mutation |
| Q36780130 | Herpes simplex virus type 1 gene products required for DNA replication: identification and overexpression. |
| Q34070145 | Herpes simplex virus type 1-based amplicon vector systems |
| Q42448457 | Herpes simplex virus type 1/adeno-associated virus hybrid vectors |
| Q34341823 | Herpes simplex virus type 1/adeno-associated virus hybrid vectors mediate site-specific integration at the adeno-associated virus preintegration site, AAVS1, on human chromosome 19. |
| Q34341816 | Herpes simplex virus type 1/adeno-associated virus rep(+) hybrid amplicon vector improves the stability of transgene expression in human cells by site-specific integration |
| Q40395117 | Herpes simplex virus type-1 amplicon vectors for vaccine generation in acute lymphoblastic leukemia |
| Q45788035 | Herpes simplex virus vector system: analysis of its in vivo and in vitro cytopathic effects |
| Q40599511 | Herpes simplex virus vectors for gene therapy |
| Q35863367 | Herpes simplex virus-based vectors |
| Q39320351 | Herpesvirus Capsid Assembly and DNA Packaging. |
| Q40852248 | Herpesviruses: expression of genes in postmitotic brain cells |
| Q39601616 | Hexamethylene bisacetamide leads to reduced helper virus-free HSV-1 amplicon expression titers via suppression of ICP0. |
| Q44528496 | Hippocampal infection with HSV-1-derived vectors expressing an NMDAR1 antisense modifies behavior |
| Q39872953 | Human cytomegalovirus clinical isolates carry at least 19 genes not found in laboratory strains. |
| Q24800764 | Human cytomegalovirus plasmid-based amplicon vector system for gene therapy |
| Q35881706 | Identification and analysis of a lytic-phase origin of DNA replication in human herpesvirus 7. |
| Q45806757 | Identification of a gene function of herpes simplex virus type 1 essential for amplification of simian virus 40 DNA sequences in transformed hamster cells |
| Q36655634 | Identification of a lytic-phase origin of DNA replication in human herpesvirus 6B strain Z29. |
| Q48637450 | Identification of a somatodendritic targeting signal in the cytoplasmic domain of the transferrin receptor. |
| Q36826810 | Identification of herpes simplex virus type 1 genes required for origin-dependent DNA synthesis |
| Q35852638 | Identification of human telomeric repeat motifs at the genome termini of human herpesvirus 7: structural analysis and heterogeneity |
| Q37392882 | Immune responses to herpesviral vectors |
| Q35131218 | Immune responses to replication-defective HSV-1 type vectors within the CNS: implications for gene therapy |
| Q48489387 | In situ PCR for in vivo detection of foreign genes transferred into rat brain |
| Q45882772 | In vivo episomal maintenance of a herpesvirus saimiri-based gene delivery vector |
| Q45467028 | In vivo gene transfer to the rat retina using herpes simplex virus type 1 (HSV-1)-based amplicon vectors |
| Q57020987 | In vivo methods for acute modulation of gene expression in the central nervous system |
| Q37689072 | Infection of cultured central nervous system neurons with a defective herpes simplex virus 1 vector results in stable expression of Escherichia coli beta-galactosidase |
| Q39839678 | Infection with herpes simplex type 1-based amplicon vectors results in an IRF3/7-dependent, TLR-independent activation of the innate antiviral response in primary human fibroblasts |
| Q45864617 | Infectious Delivery and Expression of a 135 kb Human FRDA Genomic DNA Locus Complements Friedreich's Ataxia Deficiency in Human Cells |
| Q28368363 | Inhibition of herpes simplex virus replication by a 2-amino thiazole via interactions with the helicase component of the UL5-UL8-UL52 complex |
| Q40140794 | Integration of active human beta-galactosidase gene (100 kb) into genome using HSV/AAV amplicon vector |
| Q33569553 | Interaction of origin binding protein with an origin of replication of herpes simplex virus 1. |
| Q39612239 | Intracellular Cre-mediated deletion of the unique packaging signal carried by a herpes simplex virus type 1 recombinant and its relationship to the cleavage-packaging process |
| Q28775738 | Intragenomic linear amplification of human herpesvirus 6B oriLyt suggests acquisition of oriLyt by transposition |
| Q40087350 | Intranuclear accumulation of subgenomic noninfectious human cytomegalovirus DNA in infected cells in the presence of ganciclovir |
| Q36825714 | Isolation and characterization of herpes simplex virus type 1 host range mutants defective in viral DNA synthesis |
| Q39871031 | Long-term expression in sensory neurons in tissue culture from herpes simplex virus type 1 (HSV-1) promoters in an HSV-1-derived vector |
| Q42280576 | Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain |
| Q58009224 | Modifications in the C Terminus of the Synaptosome-associated Protein of 25 kDa (SNAP-25) and in the Complementary Region of Synaptobrevin Affect the Final Steps of Exocytosis |
| Q36864619 | Molecular basis for interference of defective interfering particles of pseudorabies virus with replication of standard virus |
| Q37895474 | Molecular biology of varicella zoster virus. |
| Q36683100 | Mutations in a herpes simplex virus type 1 origin that inhibit interaction with origin-binding protein also inhibit DNA replication |
| Q26802140 | Neuroanatomy goes viral! |
| Q40329807 | Neuronal precursor-restricted transduction via in utero CNS gene delivery of a novel bipartite HSV amplicon/transposase hybrid vector |
| Q43678221 | Neuroprotective effects of an adenoviral vector expressing the glucose transporter: a detailed description of the mediating cellular events |
| Q40959993 | Novel biologic therapies for malignant gliomas. Antiangiogenesis, immunotherapy, and gene therapy. |
| Q45753096 | Novel synthesis and release of GABA in cerebellar granule cell cultures after infection with defective herpes simplex virus vectors expressing glutamic acid decarboxylase |
| Q37638624 | Nucleoprotein complex formed between herpes simplex virus UL9 protein and the origin of DNA replication: inter- and intramolecular interactions |
| Q36902758 | Nucleotide sequence and structural features of a novel US-a junction present in a defective herpes simplex virus genome. |
| Q39058604 | Oncolytic viral therapy with a combination of HF10, a herpes simplex virus type 1 variant and granulocyte-macrophage colony-stimulating factor for murine ovarian cancer |
| Q45401234 | Oncolytic virotherapy with an HSV amplicon vector expressing granulocyte-macrophage colony-stimulating factor using the replication-competent HSV type 1 mutant HF10 as a helper virus |
| Q73326549 | One giant genomic leap for gene transfer technology |
| Q49108925 | Overexpression of the glucose transporter gene with a herpes simplex viral vector protects striatal neurons against stroke |
| Q33848855 | Packaging of genomic and amplicon DNA by the herpes simplex virus type 1 UL25-null mutant KUL25NS |
| Q40304976 | Plasmid DNA sequences present in conventional herpes simplex virus amplicon vectors cause rapid transgene silencing by forming inactive chromatin |
| Q30465140 | Preferential addition of newly synthesized membrane protein at axonal growth cones |
| Q35757133 | Preproenkephalin promoter yields region-specific and long-term expression in adult brain after direct in vivo gene transfer via a defective herpes simplex viral vector |
| Q35216652 | Problems in the use of herpes simplex virus as a vector |
| Q33884957 | Production of viral vectors for gene therapy applications |
| Q45411920 | Properties of a herpes simplex virus multiple immediate-early gene-deleted recombinant as a vaccine vector |
| Q33799437 | Pseudotyping of glycoprotein D-deficient herpes simplex virus type 1 with vesicular stomatitis virus glycoprotein G enables mutant virus attachment and entry |
| Q24634231 | Pseudovirions as vehicles for the delivery of siRNA |
| Q36698650 | Purification and characterization of UL9, the herpes simplex virus type 1 origin-binding protein |
| Q38613625 | Recognition mechanisms in the synthesis of animal virus DNA. |
| Q40081264 | Recombinant vaccinia viruses as new live vaccines |
| Q40390643 | Recombinational hotspots within the herpes simplex virus DNA polymerase gene? |
| Q30482492 | Reduced pathology and improved behavioral performance in Alzheimer's disease mice vaccinated with HSV amplicons expressing amyloid-beta and interleukin-4. |
| Q36569912 | Regulatable gene expression systems for gene therapy |
| Q36157542 | Regulatable gene expression systems for gene therapy applications: progress and future challenges |
| Q36851094 | Regulation of cytomegalovirus gene expression: alpha and beta promoters are trans activated by viral functions in permissive human fibroblasts |
| Q34477918 | Replication-defective viruses as vaccines and vaccine vectors |
| Q36618719 | Requirement for double-strand breaks but not for specific DNA sequences in herpes simplex virus type 1 genome isomerization events. |
| Q33545312 | Restorative gene therapy approaches to Parkinson's disease |
| Q35036540 | Retinal ganglion cell differentiation in cultured mouse retinal explants |
| Q40104126 | Selectable recombinant herpesvirus saimiri is capable of persisting in a human T-cell line |
| Q36784220 | Sequence requirements for DNA rearrangements induced by the terminal repeat of herpes simplex virus type 1 KOS DNA |
| Q35588066 | Sequence-nonspecific replication of transfected plasmid DNA in poxvirus-infected cells |
| Q38341045 | Sequences within the herpesvirus-conserved pac1 and pac2 motifs are required for cleavage and packaging of the murine cytomegalovirus genome. |
| Q48377640 | Signals for site-specific cleavage of HSV DNA: maturation involves two separate cleavage events at sites distal to the recognition sequences |
| Q40642190 | Single HSV-amplicon vector mediates drug-induced gene expression via dimerizer system. |
| Q33825579 | Single-step conversion of cells to retrovirus vector producers with herpes simplex virus-Epstein-Barr virus hybrid amplicons |
| Q34045705 | Site-directed mutagenesis of large DNA palindromes: construction and in vitro characterization of herpes simplex virus type 1 mutants containing point mutations that eliminate the oriL or oriS initiation function |
| Q37818222 | Sitimagene ceradenovec: a gene-based drug for the treatment of operable high-grade glioma |
| Q41450039 | Somatic gene transfer approaches to manipulate neural networks |
| Q40127499 | Specificity of cleavage in replicative-form DNA of bovine herpesvirus 1. |
| Q37822930 | Strategies for the development of cell lines for ex vivo gene therapy in the central nervous system |
| Q40846780 | Synapto-pHluorins: chimeras between pH-sensitive mutants of green fluorescent protein and synaptic vesicle membrane proteins as reporters of neurotransmitter release |
| Q40182069 | Synergistic effects of deleting multiple nonessential elements in nonreplicative HSV-1 BAC genomic vectors play a critical role in their viability. |
| Q39595544 | Tamplicon-7, a novel T-lymphotropic vector derived from human herpesvirus 7 |
| Q45864772 | Targeted transgene integration into transgenic mouse fibroblasts carrying the full-length human AAVS1 locus mediated by HSV/AAV rep(+) hybrid amplicon vector. |
| Q37895283 | Targeting the central nervous system with herpes simplex virus / Sleeping Beauty hybrid amplicon vectors |
| Q40419422 | The DNA replication origins of herpes simplex virus type 1 strain Angelotti |
| Q36656286 | The UL5 gene of herpes simplex virus type 1: isolation of a lacZ insertion mutant and association of the UL5 gene product with other members of the helicase-primase complex |
| Q36902169 | The alpha sequence of the cytomegalovirus genome functions as a cleavage/packaging signal for herpes simplex virus defective genomes |
| Q36685367 | The conserved helicase motifs of the herpes simplex virus type 1 origin-binding protein UL9 are important for function |
| Q45855769 | The herpes simplex virus 1 origin binding protein: a DNA helicase |
| Q37676359 | The herpes simplex virus amplicon: analyses of cis-acting replication functions |
| Q36687506 | The herpes simplex virus type 1 (HSV-1) a sequence serves as a cleavage/packaging signal but does not drive recombinational genome isomerization when it is inserted into the HSV-2 genome |
| Q36796087 | The herpes simplex virus type 1 UL42 gene product: a subunit of DNA polymerase that functions to increase processivity |
| Q33229421 | The herpes simplex virus type 1 vhs-UL41 gene secures viral replication by temporarily evading apoptotic cellular response to infection: Vhs-UL41 activity might require interactions with elements of cellular mRNA degradation machinery |
| Q36063602 | The infectious BAC genomic DNA expression library: a high capacity vector system for functional genomics |
| Q40788732 | The inhibition of phosphatidylinositol-3-kinase induces neurite retraction and activates GSK3. |
| Q40885287 | Therapeutic efficiency of IL-2 gene transduced tumor vaccine for head and neck carcinoma |
| Q36913463 | Transcriptional and genetic analyses of the herpes simplex virus type 1 genome: coordinates 0.29 to 0.45 |
| Q37691015 | Transfer of Anti-Rotavirus Antibodies during Pregnancy and in Milk Following Maternal Vaccination with a Herpes Simplex Virus Type-1 Amplicon Vector. |
| Q36739755 | Translational considerations for CNS gene therapy |
| Q39653722 | UL84-independent replication of human cytomegalovirus strain TB40/E |
| Q35903203 | Update on herpesvirus amplicon vectors |
| Q36370376 | Use of Adeno-Associated and Herpes Simplex Viral Vectors for In Vivo Neuronal Expression in Mice |
| Q33201424 | Use of amplicon-6 vectors derived from human herpesvirus 6 for efficient expression of membrane-associated and -secreted proteins in T cells |
| Q45722483 | Use of codon-modified, red-shifted variants of green fluorescent protein genes to study virus-mediated gene transfer |
| Q36780156 | Use of viral vectors for the development of vaccines |
| Q36117060 | Vaccinia recombinants as vaccine vectors |
| Q36150489 | Versatility of gene therapy vectors through viruses |
| Q37945189 | Viral hybrid vectors for somatic integration - are they the better solution? |
| Q43747177 | Viral vector-mediated expression of K+ channels regulates electrical excitability in skeletal muscle |
| Q37946113 | Viral vectors for gene delivery to the central nervous system |
| Q35120134 | Viral vectors for gene delivery to the nervous system |
| Q28141424 | Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics |
| Q41235446 | Viral vectors for modulating gene expression in neurons |
| Q38746238 | Viral vectors for therapy of neurologic diseases |
| Q39689760 | Virion-associated cofactor high-mobility group DNA-binding protein-1 facilitates transposition from the herpes simplex virus/Sleeping Beauty amplicon vector platform |
| Q34836871 | Virus-based gene delivery systems |
| Q36864623 | cis Functions involved in replication and cleavage-encapsidation of pseudorabies virus |
Search more.